Rockley Photonics advances Non-Invasive Blood Glucose Monitoring

  • Rockley has made rapid progress towards noninvasive optical measurement of glucose through benchtop and human studies.
  • Measurement of glucose in simulated skin samples with Rockley’s proprietary photonic IC (PIC) chip technology, in a benchtop system resulted in a prediction accuracy of 5mg/dL.
  • Rockley performed a rigorous human study involving 40 diabetic subjects over a 10-week period, which mitigated many common pitfalls of less advanced protocols.
  • Rockley demonstrated the capability of its SWIR (short-wave infrared) measurement technique, including the requisite radiant powers, wavelength range, and optical resolution that are critical to enabling non-invasive glucose sensing in a wearable form factor.

Rockley Photonics continues to make rapid progress towards noninvasive glucose sensing using its proprietary silicon photonics platform. The technology platform enables short-wave infrared (SWIR) spectroscopy to be translated to a miniaturized, wearable form factor capable of making noninvasive biomarker measurements in humans. Through a combination of benchtop sensor verification with both simulated human skin and during preliminary human studies, Rockley has engineered the SWIR platform to measure glucose.

Recent measurements performed using Rockley’s PIC technology in a benchtop version with a complex simulated tissue model showed that the technology is capable of measuring glucose with an accuracy of 5mg/dL. The results of an initial IRB-approved study involving 40 Type I and Type II diabetic subjects over a 10-week period also demonstrated significant progress towards the development of a noninvasive wearable glucose monitor. The study was conducted with attention to avoid spurious correlations and allowed for critical technology performance characteristics to be determined.

Mark A. Arnold, Ph.D. the Edwin B. Green Chair in Laser Chemistry, professor of chemistry and director of the Center for Biocatalysis and Bioprocessing (CBB) at the University of Iowa and leading contributor to Rockley’s scientific advisory board, spoke about the quality of the work at Rockley. “Rockley has been open with the details of their data and subsequent analysis and invited my critique of all aspects of their work. Rockley has assembled a world class team around the system design, quantitative algorithm development, and clinical experimental design.”

Speaking about the progress of the silicon photonics platform, Dr. Mark Arnold said, “Rockley has demonstrated that its technology can enable a sensor that has the requisite radiant powers, wavelength range, and optical resolution needed to make these difficult measurements in real-world products.”

Commenting on the capability of the novel sensing technology, Dr. Andrew Rickman, CEO and Chairman, spoke to the results of the studies and Rockley’s future implementation in wearables. “We are excited that our unique PIC technology is enabling us to noninvasively and accurately measure unique biomarkers in a very small form factor.” He continued, “The results confirm that Rockley’s integrated silicon photonic technology and novel processing of the SWIR signal offers a unique opportunity to realize the goal of a wearable, noninvasive glucose sensor for a host of medical applications.”

Visit AITechPark for cutting-edge Tech Trends around AI, ML, Cybersecurity, along with AITech News, and timely updates from industry professionals!

Related posts

Koneksa Announces Partnership with Beacon Biosignals

Business Wire

Ellipsis Health to sponsor the APEC Summit

PR Newswire

Fapon Group inked a memorandum of cooperation with C.I.C.

PR Newswire